Eden Biodesign and Stealthyx Therapeutics sign deal to develop enhanced treatment for rheumatoid arthritis
The product will incorporate Stealthyx Therapeutics' proprietary Prothyx technology that has been developed by Professor Yuti Chernajovsky at St. Bartholomews Hospital and The London, Queen Mary's School of Medicine and Dentistry, University of London. Prothyx harnesses the properties of a naturally occurring peptide to confer stability and disease targeting biological therapeutics resulting in improved efficacy and lower side effect profile.
This project has been funded by the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA).
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.